Novo Nordisk's CEO said on September 23 the company is open to a direct US listing, according to the Financial Times. If you hold the Ozempic maker through its US ADR or its Copenhagen-listed ordinary shares, here is what a US listing would mechanically change, and how to fold a cross-listed holding into a single position without double-counting.
What did Novo Nordisk's CEO actually say about a US listing?
On September 23, Novo Nordisk's CEO told the Financial Times the company is open to a direct US listing, meaning ordinary shares could trade on a US exchange rather than only through a depositary receipt. That is an expression of openness, not a filing, a date, or an approved plan.
Here is what is confirmed versus still unknown as of now:
- Confirmed: the CEO said a direct US listing is on the table.
- Unknown: the venue (NYSE or Nasdaq), the timing, whether the existing ADR would be retired, and the ratio at which anything converts.
- Unknown: whether the Copenhagen listing on Nasdaq Copenhagen stays as the primary line.
Everything below explains the mechanics so you can check your own exposure. None of it is a recommendation to trade.
ADR vs local shares: what is the difference for a Novo Nordisk holder?
An ADR (American Depositary Receipt) is a US-traded certificate that represents shares of a foreign company held on deposit by a bank, while local shares are the ordinary shares trading on the home exchange. For Novo Nordisk that means the US line NVO versus the Copenhagen line NOVO-B.CO.
The two lines track the same underlying business but are not interchangeable in your account. Key differences a holder feels:
- Currency: NVO settles in US dollars; NOVO-B.CO settles in Danish krone (DKK).
- Ratio: Novo Nordisk's ADR represents one ordinary B share, so the prices roughly line up after the USD/DKK conversion.
- Dividends: ADR holders receive dividends in USD net of Danish withholding tax; local holders receive DKK.
- Depositary fees: ADRs can carry small custody or pass-through fees that local shares do not.
If you want the broader picture on tracking a foreign name across venues, our guide on tracking stocks and crypto together in one app covers the multi-currency mechanics that apply here too.
How would a direct US listing change what you hold?
A direct US listing would put Novo Nordisk's ordinary shares onto a US exchange, which is structurally different from the ADR you may hold today. The important word is could, because the company has not said what happens to the existing NVO ADR.
The scenarios a holder should understand
There are a few ways this typically plays out, and each has a different effect on your position:
- New line added, ADR stays: you would simply have another venue for the same company. Your NVO or NOVO-B.CO holding is untouched.
- ADR converted to ordinary shares: your depositary receipts are exchanged for ordinary shares at a set ratio, and your cost basis carries across at that ratio.
- ADR retired, holders must act: less common, but a depositary can terminate a program, giving holders a window to convert or sell.
None of these is confirmed for Novo Nordisk. This is why the practical move is to watch for the official terms rather than pre-position around a rumour.
ADR vs Copenhagen shares vs a future US ordinary line
The table below compares the three ways you might end up holding Novo Nordisk. Treat the third column as hypothetical until the company publishes terms.
| Feature | ADR (NVO) | Copenhagen (NOVO-B.CO) | Future US ordinary (hypothetical) |
|---|---|---|---|
| Currency | USD | DKK | USD |
| Instrument | Depositary receipt | Ordinary B share | Ordinary share |
| Depositary fee | Possible | None | None |
| Dividend paid in | USD (net of DK tax) | DKK | USD (net of DK tax) |
The point of the table is not to pick one. It is to show that currency, fees, and instrument type are the only things that really differ, while the business you own is identical.
How to consolidate a cross-listed Novo Nordisk holding into one position
To consolidate a cross-listed holding, you record every lot against a single company entity and convert all values into one display currency, so the two tickers stop showing as two separate stocks. The shares are economically the same company, so double-counting them across NVO and NOVO-B.CO overstates your line and distorts your allocation.
The manual method, step by step
- Pick a reference currency for the combined position, usually USD or DKK.
- Convert each lot at the exchange rate on its purchase date so cost basis stays accurate.
- Normalise the share ratio. Because Novo Nordisk's ADR equals one ordinary share, the count is straightforward, but always confirm the ratio for any ADR.
- Sum the shares and the total cost to get a single weighted average entry price.
This is tedious in a spreadsheet, especially with dividends and FX drift, which is one reason many holders move off manual grids. Our comparison of a portfolio tracker versus a spreadsheet walks through exactly where spreadsheets break on multi-currency positions.
How PortfolioTrackr handles a cross-listed position
PortfolioTrackr lets you group holdings under one company and display everything in your chosen currency, so NVO in USD and NOVO-B.CO in DKK roll up into a single Novo Nordisk line. Because it covers 100 stock exchanges and 67 currencies, both listings live in the same dashboard without you juggling two apps or two FX rates.
- Enter both lots manually, by CSV, or by broker screenshot, no broker connection required.
- See one weighted average cost and one total gain across both venues.
- Keep the underlying lots visible so you retain the correct cost basis if a conversion happens.
Should you connect a broker, or enter it manually?
Connecting a broker is optional; manual entry, voice, text, CSV, and broker screenshots all work on every plan. Whether you connect depends on where your Novo Nordisk shares actually sit.
Your practical options:
- Direct integrations: Alpaca, Bybit, and Interactive Brokers sync automatically.
- SnapTrade bridge: 35 additional brokers connect through SnapTrade, useful if your NVO shares are at a US broker.
- Manual entry: the reliable route for a Copenhagen line held at a European broker that does not have an integration.
If your US-side shares sit at a mainstream broker, our walkthrough on connecting your brokerage account to a portfolio tracker covers the setup, and the single dashboard for Alpaca, IBKR, Schwab and Robinhood shows how mixed sources roll up together.
What can you check right now as a Novo Nordisk holder?
You can check your own exposure and your alert setup today without waiting for any listing decision. Checking is not the same as acting, and nothing here tells you to buy or sell.
Practical things a holder can review:
- Your total Novo Nordisk exposure across NVO, NOVO-B.CO, and any funds that hold it.
- Which currency each lot is denominated in, since a US listing shifts more of your exposure into USD terms.
- Whether the two lines are double-counted in your current tracker or spreadsheet.
- Whether you have a price alert set against your own levels.
On PortfolioTrackr, every position and every watchlist level is checked once a minute, around the clock, so you hear within a minute of your level being hit. The tracker reports status against your own targets, for example still below target, Target 1 reached, or stop-loss level reached. Watchlist alerts are on every plan. It reports status; it does not tell you what to do.
The bottom line
Novo Nordisk being open to a US listing is news about venue and structure, not about the underlying business, and no terms have been published as of September 23. For holders, the concrete work is understanding whether you own the NVO ADR or the NOVO-B.CO ordinary shares, and making sure they show up as one position rather than two.
Consolidating now means that if a conversion ever arrives, your cost basis and exposure are already clean. If you want to see how different tools handle cross-listed and multi-currency holdings, our real-data comparison of portfolio trackers is a good next read.
Connect your broker and stop typing trades
42 brokers through the SnapTrade bridge on paid Pro and Lifetime plans. Alpaca, Bybit and Interactive Brokers also connect directly on every plan. Positions and cost basis sync automatically, across as many accounts as you hold.
Connect Your Broker
Frequently asked questions
Is Novo Nordisk's US ADR the same as its Copenhagen shares?
They represent the same company but are not interchangeable. The US ADR (NVO) trades in US dollars and one ADR equals one ordinary B share, while the Copenhagen line (NOVO-B.CO) trades in Danish krone. Currency, possible depositary fees, and dividend handling differ, but the underlying business is identical.
Will a US listing force me to convert my Novo Nordisk ADR?
It is not confirmed. A direct US listing could add a new ordinary-share line while leaving the ADR untouched, or a depositary could convert or retire the ADR at a set ratio. As of September 23 the company has published no terms, so wait for the official conversion details before assuming anything changes.
How do I track Novo Nordisk on two exchanges as one holding?
Group both lots under one company and convert everything into a single display currency. In PortfolioTrackr you can combine NVO in USD and NOVO-B.CO in DKK into one Novo Nordisk line, since it covers 100 exchanges and 67 currencies, giving you one weighted average cost across both venues.
Do I need to connect a broker to track a cross-listed stock?
No. Connecting a broker is optional. You can add both listings by manual entry, voice, text, CSV, or broker screenshot on every plan. The SnapTrade bridge connects 42 brokers on paid Pro and Lifetime plans, and if your shares sit at Alpaca, Bybit or Interactive Brokers you can also sync directly on every plan.
What happens to my cost basis if an ADR converts to ordinary shares?
Your cost basis typically carries across at the conversion ratio, so a one-to-one ADR conversion keeps your per-share cost intact. Keep your original lots visible in your tracker so the basis stays accurate. Exact tax treatment depends on your jurisdiction, so confirm with the official terms when published.